Report Highlights

The U.S.'s Role in the Global Preclinical CRO Supply Chain

The United States is the dominant hub in the global preclinical CRO supply chain, accounting for approximately 38% of global preclinical outsourcing revenue. U.S.-based CROs serve as the primary execution nodes for FDA-compliant GLP toxicology studies, which are mandatory for IND submissions targeting the U.S. market. Major facilities operated by Charles River Laboratories in Mattawan, Michigan and Reno, Nevada; Labcorp Drug Development in Madison, Wisconsin; and Covance in Greenfield, Indiana collectively process thousands of regulated study reports annually. The U.S. market is both a production center and a regulatory gateway — international sponsors from Europe, Japan, and South Korea route studies through U.S. CROs specifically to satisfy FDA expectations before pivoting to multinational clinical programs.

The U.S. also functions as the world's largest importer of preclinical services inputs, sourcing non-human primates (NHPs) predominantly from Cambodia, Mauritius, and China before 2020, with ongoing geopolitical disruption forcing a costly pivot to domestic breeding programs. WuXi AppTec's U.S. operations and Eurofins' network of domestic laboratories represent significant foreign-owned nodes within the domestic supply chain, complicating the narrative of fully domestic service delivery. Exports of U.S. preclinical data packages — in the form of regulatory dossiers and study reports — flow primarily to EMA, PMDA, and Health Canada review bodies, making the U.S. a net exporter of validated preclinical evidence even as it imports biological inputs at scale.

Growth Drivers for U.S. Preclinical CRO Trade and Production

Three supply chain dynamics are accelerating U.S. preclinical CRO capacity expansion. First, the surge in novel modality pipelines — including RNA therapeutics, cell and gene therapies, and antibody-drug conjugates — has created demand for specialized in vivo and in vitro models that only a handful of U.S. CROs currently operate at GLP scale. Charles River's acquisition of Cognate BioServices and Explora BioLabs reflects deliberate capacity investment in this segment. Second, NIH grant funding exceeding USD 45 billion annually sustains a deep pipeline of academic-stage assets requiring preclinical validation before licensing or venture-backed development, feeding a steady volume of early-phase outsourcing mandates into the CRO ecosystem.

Third, the BIOSECURE Act — advancing through U.S. Congress with bipartisan support — is structurally redirecting preclinical outsourcing away from Chinese CROs including WuXi AppTec and BGI-affiliated entities. Sponsors that previously split preclinical packages between U.S. and Chinese vendors are consolidating back to domestic providers to pre-empt compliance risk, adding an estimated 15–20% volume uplift to U.S.-based GLP toxicology and bioanalytical service providers through 2027. This legislative driver is capacity-constrained rather than demand-constrained, making infrastructure investment the binding variable for domestic CRO growth.

Supply Chain Risks and Trade Barriers

The most acute supply chain risk in the U.S. preclinical CRO market is NHP availability. Following the 2022 Cambodian NHP export suspension and sustained post-pandemic disruption to Chinese supply routes, U.S. CROs face chronic shortages of cynomolgus macaques essential for immunotoxicology and biologic safety studies. The National Primate Research Centers have expanded domestic breeding, but lead times of 18–24 months for domestically bred NHPs create a structural lag that compounds study scheduling risk for biosimilar and biologic sponsors. Per-animal costs have increased over 300% since 2021, directly inflating sponsor study budgets and, in some cases, forcing protocol modifications that reduce regulatory defensibility.

A secondary but growing risk is the dependency of U.S. CRO laboratories on imported specialty reagents, reference standards, and cell culture consumables with limited domestic alternatives. Trade friction with China — the primary source of several critical bioanalytical reagents — introduces both cost volatility and availability uncertainty into laboratory operations. Additionally, U.S. export controls on certain biological materials complicate collaborative preclinical work with European and Asian sponsors, adding compliance overhead that smaller CROs are poorly equipped to manage. The concentration of GLP-certified capacity among five or fewer large CROs creates systemic vulnerability if any single operator experiences a facility failure or regulatory action.

Trade and Investment Opportunities in U.S. Preclinical CRO

The BIOSECURE Act-driven repatriation of preclinical outsourcing creates an immediate investment thesis for greenfield GLP toxicology capacity in the U.S. mid-tier CRO segment. Companies that can deliver full-package preclinical programs — combining pharmacology, safety pharmacology, ADME, and GLP toxicology under one roof — with 90-day booking windows will command premium pricing through at least 2028. Private equity firms including Ampersand Capital Partners and EQT AB have already identified this gap, with multiple bolt-on acquisition programs targeting sub-scale U.S. toxicology and bioanalytical labs. The window for capacity investment before the market self-corrects is approximately 24–36 months.

Inbound foreign direct investment from European CROs — specifically SGS Life Sciences, Evotec, and Celerion — targeting U.S. GLP laboratory infrastructure represents a significant near-term trade flow. European operators with established EMA-compliant study designs are positioning U.S. subsidiaries as dual-regulatory execution nodes capable of generating data simultaneously acceptable to FDA and EMA, a capability commanding 20–30% fee premiums over single-jurisdiction providers. Logistics hub development around established biotech clusters — Boston-Cambridge, San Francisco Bay Area, and Research Triangle Park — is also attracting CRO facility investment, with proximity to sponsor sites reducing study initiation timelines and enabling more frequent protocol interactions that improve study quality and first-pass acceptance rates by regulatory agencies.

Market at a Glance

Leading Market Participants

• Charles River Laboratories International
• Labcorp Drug Development (Covance)
• ICON plc
• Eurofins Scientific
• WuXi AppTec
• Envigo (Inotiv)
• Pacific Biosciences (PacBio)
• SGS Life Sciences
• Celerion
• Absorption Systems (Cyprotex)

Regulatory and Trade Policy Environment

The U.S. preclinical CRO market operates under FDA Good Laboratory Practice regulations codified at 21 CFR Part 58, which govern facility standards, study conduct, archiving, and quality assurance for all regulated nonclinical safety studies submitted in IND and NDA filings. The FDA's Mutual Recognition Agreement with the European Union, effective for GMP inspections since 2019, does not extend to GLP preclinical facilities, meaning U.S.-generated study reports submitted to EMA must satisfy separate OECD GLP compliance standards — a dual compliance burden that increases operating costs for CROs serving multinational sponsors. EPA additionally enforces GLP standards under 40 CFR Parts 160 and 792 for agrochemical and environmental studies, creating parallel regulatory tracks within the same facility infrastructure.

The BIOSECURE Act, if enacted in its current form, will prohibit U.S. federal contractors and grant recipients from using preclinical CRO services provided by designated Chinese biotechnology companies, including WuXi AppTec and its U.S. subsidiaries. This creates an immediate trade policy barrier for sponsors currently using WuXi's Burlington, Massachusetts and Plainsboro, New Jersey facilities for regulated studies. The U.S.-Mexico-Canada Agreement (USMCA) facilitates some cross-border preclinical work, particularly specimen transport and bioanalytical sample processing between U.S. and Canadian facilities, but does not harmonize regulatory standards. Import duties on laboratory animals and biological specimens remain subject to USDA and CDC permit requirements that add two to four weeks to cross-border sample transit timelines.

U.S. Preclinical CRO Supply Chain Outlook to 2032

By 2032, the U.S. preclinical CRO supply chain will be materially restructured around three shifts: domestic NHP breeding capacity reaching self-sufficiency for routine biologics studies, AI-accelerated in vitro model adoption reducing but not eliminating in vivo study volumes, and a bifurcated competitive landscape separating full-service GLP platforms from specialized niche providers. Domestic NHP breeding programs funded through NIH and private CRO investment are projected to close approximately 60% of the current supply gap by 2029, reducing per-animal cost premiums and restoring scheduling predictability for NHP-dependent study designs. This will disproportionately benefit mid-tier U.S. CROs that currently cannot compete for NHP-intensive biologic programs due to sourcing constraints.

The integration of organoid platforms, microphysiological systems, and AI-driven toxicity prediction tools will shift early-stage screening away from rodent models by 2030, compressing the volume of exploratory in vivo studies while leaving GLP regulatory toxicology volumes largely intact. CROs investing now in computational toxicology capabilities — including Certara's Phoenix platform integration and Simulations Plus partnerships — will differentiate on study design efficiency rather than price. The net effect will be higher revenue per study, lower animal use per program, and a U.S. CRO sector that functions increasingly as a science-driven value-added service provider rather than a volume-based animal study contractor, reinforcing the country's position at the top of the global preclinical value chain.